The SP spent the last 3 years eroding 80% due to clinical program blowouts. Not sure how you missed this?
Fortunately, the development of RC220 was partly responsible for these delays. RC220 is also responsible for more than doubling our patent runway and added many multiples to our TAM.
Thankfully, RC220 is now knocking on the clinic door. The market is forward looking and is starting to price that in. If RAC manage to dose a patient and CPACS is clinically validated, then shareholders should have at least two opportunities to derisk in the next 12 months at what I'd presume a better exit than today offers.
Significant milestones in the near, mid and longer term. The perfect storm.
[WEBINAR REPLAY] What it takes to get a new drug to market in Australia, page-31
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
0.000(0.00%) |
Mkt cap ! $247.1M | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.45 | $1.35 | $254.2K | 185.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 212 | $1.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 5981 | 3 |
View Market Depth
| Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |